Peptidoglycan precursors

Peptidoglycan precursors are essential intermediate molecules in the biosynthesis of the bacterial cell wall, which is particularly thick and critical for the survival of Gram-positive bacteria. The most clinically significant target among these precursors is Lipid II and its terminal D-alanyl-D-alanine (D-Ala-D-Ala) dipeptide moiety. Glycopeptide antibiotics, such as vancomycin, bind with high affinity to this D-Ala-D-Ala terminus, creating a physical barrier that prevents penicillin-binding proteins (PBPs) from performing the transglycosylation and transpeptidation steps necessary for peptidoglycan polymerization. This inhibition leads to a weakened cell wall, resulting in osmotic lysis and bacterial cell death. Because the peptidoglycan biosynthetic pathway is unique to prokaryotes, these precursors serve as highly selective targets for antimicrobial therapy, minimizing off-target effects in human hosts. However, the emergence of resistance, characterized by the modification of the precursor to D-alanyl-D-lactate, remains a significant challenge in treating infections caused by resistant Gram-positive pathogens.

Other names

Lipid IID-alanyl-D-alanine terminusMurein precursorsUDP-N-acetylmuramyl-pentapeptideBactoprenol-bound peptidoglycan intermediates

Inhibition of bacterial cell wall synthesis by binding to peptidoglycan precursors (specifically the D-Ala-D-Ala terminus or Lipid II), thereby sterically hindering transglycosylation and transpeptidation reactions required for cross-linking.